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In vitro antistaphylococcal activities of panduratin A, a natural chalcone compound isolated from Kaempfe-
ria pandurata Roxb, were compared to those of commonly used antimicrobials against clinical staphylococcal
isolates. Panduratin A had a MIC at which 90% of bacteria were inhibited of 1 g/ml for clinical staphylococcal
isolates and generally was more potent than commonly used antimicrobials.
Staphylococci are frequently refractory to many new and
commonly used antimicrobial agents and have become a prob-
lem in recent years (8, 12, 17). Methicillin (meticillin)-resistant
Staphylococcus aureus (MRSA) infections have emerged as a
worldwide problem, and clinical strains of MRSA exhibit re-
duced susceptibility to antimicrobial agents (18). Moreover,
coagulase-negative staphylococci are well established due to
nosocomial bacteremia and indwelling medical device-associ-
ated infection, showing increased multidrug resistance (1, 14).
Thus, the identification of novel agents effective in inhibiting
these strains has gained renewed urgency (7). In addition,
there is renewed interest in plants with antimicrobial proper-
ties as a consequence of current problems associated with the
use of antibiotics (4, 9). Panduratin A, a natural chalcone
compound isolated from the rhizome of fingerroot (Kaempferia
pandurata Roxb.), has been reported to possess antibacterial
activity against Prevotella intermedia, Prevotella loescheii, Por-
phyromonas gingivalis, Propionibacterium acnes, and Streptococ-
cus mutans, as well as antibiofilm activity against multispecies
oral biofilms in vitro (6, 13, 15, 16). However, antimicrobial
activities of panduratin A against other pathogenic bacteria,
such as staphylococci, have not yet been investigated.
In this study, we compared the in vitro activities of pandu-
ratin A against MRSA, methicillin-susceptible S. aureus
(MSSA), methicillin-resistant coagulase-negative staphylo-
cocci (MRCNS), and methicillin-susceptible coagulase-nega-
tive staphylococci (MSCNS) with those of treatments with
available antimicrobial agents, such as ampicillin, erythromy-
cin, gentamicin, levofloxacin, linezolid, oxacillin, tetracycline,
thymol, and vancomycin.
Clinical MRSA (n 27), MSSA (n 27), MRCNS (n 28),
and MSCNS (n  26) were obtained from the Research Insti-
tute of Bacterial Resistance, College of Medicine, Yonsei Uni-
versity, South Korea. The clinical Staphylococcus strains were
collected in 2008 from patients at a Korean tertiary-care hos-
pital. The strains were isolated from body fluids, blood, genital
secretions, pus, or sputum, of the patient. The species were
identified by conventional methods (2) or by using the Vitek
system (bioMerieux SA, Marcy l’Etoile, France) according to
the manufacturer’s instructions. Reference strains S. aureus
ATCC 29213 and Staphylococcus epidermidis ATCC 12228
from the American Type Culture Collection (Rockville, MD)
were included as controls.
Panduratin A (FIG. 1) was isolated in pure form from an
ethanol extract of Kaempferia pandurata Roxb. according to
the method of Park et al. (13). Panduratin A was dissolved in
10% dimethyl sulfoxide (DMSO) to obtain a 1,024-g/ml stock
solution. Ampicillin, erythromycin, gentamicin, tetracycline,
thymol, and vancomycin were purchased from Sigma-Aldrich.
Co. (St. Louis, MO). Levofloxacin and oxacillin were pur-
chased from Sigma-Fluka Co. (Steinheim, Germany), and lin-
ezolid was provided by Dong-A Pharmaceutical Co. (Seoul,
South Korea). Stock solutions of commercial antimicrobial
agents were prepared according to the manufacturer’s instruc-
tions.
In vitro susceptibility tests were performed in a 96-well mi-
crotiter plate to determine MICs of panduratin A and other
antimicrobial agents against 108 isolates of clinical staphylo-
cocci using standard broth microdilution methods with an in-
oculum of 5  105 CFU/ml, according to the guidelines of
CLSI standard M7-A6 (3). A twofold dilution of panduratin A
stock solution or other antimicrobial agent preparation was
mixed with the test organisms (5  105 CFU/ml) in Mueller-
Hinton broth (MHB) medium (Difco Becton Dickinson,
Sparks, MD). Column 12 of the microtiter plate contained the
highest concentrations of panduratin A or other antimicrobial
agents, and column three contained the lowest concentrations
of panduratin A or other antimicrobials agents. Column 2
served as the positive control for all samples (only medium and
inoculum or antimicrobial agent-free wells), and column 1 was
the negative control (only medium, no inoculum, and no anti-
microbial agent). Microtiter plates were incubated aerobically
at 37°C for 24 h. The MIC was defined as the lowest concen-
tration of antimicrobial agent that resulted in the complete
inhibition of visible growth.
Panduratin A was diluted in 10% DMSO, followed by two-
fold dilutions in the test wells; thus, the final concentration of
DMSO would be serially decreased. We examined the effect
of DMSO on the growth and viability of all staphylococci
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tested. DMSO at 10% was found not to affect growth or
viability of the staphylococci tested. These results suggest that
DMSO had no effect on activity and that all the antimicrobial
activity was due to panduratin A.
Minimal bactericidal concentrations (MBCs) were deter-
mined for each antimicrobial agent per Staphylococcus strain
as outlined for MICs (5). Briefly, medium (approximately 100
l) from each well showing no visible growth was spread onto
MHA (MHB supplemented with 1.5% bacterial agar) plates.
Wells in column 2, the positive controls (antimicrobial agent-
free wells), and wells in column 1, growth-negative controls,
were included for the MBC test. Plates were incubated at 37°C
for 24 h or until growth was seen in the growth-positive control
plates. MBC was defined as the lowest concentration of anti-
microbial agent at which all bacteria in the culture are killed or
the lowest concentration at which no growth occurs on MHA
plates (5, 10).
Table 1 shows the MICs and MBCs of panduratin A in
comparison to those of ampicillin, erythromycin, gentamicin,
levofloxacin, linezolid, oxacillin, tetracycline, thymol, and van-
comycin for clinical staphylococci isolates. In this study, all
isolates were susceptible to panduratin A, with MICs of 2
g/ml. In our previous report (13), the MIC of panduratin A
against P. gingivalis, P. loescheii, and S. mutans was 4 g/ml
while that of panduratin A against P. intermedia and P. acnes
was 2 g/ml (6, 13, 15). These results show that panduratin A
has activities against clinical staphylococci stronger than those
against P. gingivalis, P. loescheii, and S. mutans and comparable
or equal to those against P. intermedia and P. acnes. Moreover,
panduratin A has the capability of preventing the biofilm for-
mation of primary multispecies oral bacteria (Actinomyces vis-
cosus, S. mutans, and Streptococcus sanguis) in vitro (16). This
report suggests that panduratin A might also have the ability to
inhibit staphylococcal biofilm formation. Hence, future re-
search is necessary to determine the inhibition activity of pan-
duratin A against staphylococcal biofilm formation.
In this study, all isolates of MRSA, MSSA, MRCNS, and
MSCNS were resistant to ampicillin. However, all isolates of
MRSA, MSSA, MRCNS, and MSCNS were inhibited by 2
g/ml of panduratin A. MICs of panduratin A against all
isolates tested were much lower than those of thymol (512
g/ml), which has been reported to possess antistaphylococcal
activity (11). Moreover, most isolates of MRSA were resistant
to erythromycin, gentamicin, levofloxacin, oxacillin, and tetra-
cycline. Although all isolates of MRSA were inhibited by 2
g/ml of linezolid, these MICs of 2 g/ml were still higher
than that of panduratin A or vancomycin, which inhibited the
growth of all isolates of MRSA with MICs of 1 g/ml.
The majority of MSSA isolates were susceptible to eryth-
romycin (MIC at which 90% of bacteria were inhibited
[MIC90]  32 g/ml), gentamicin (MIC90  64 g/ml),
levofloxacin (MIC90  8 g/ml), linezolid (MIC90  4 g/
ml), oxacillin (MIC90  1 g/ml), tetracycline (MIC90  8
g/ml), and vancomycin (MIC90  0.5 g/ml). However, the
MIC90 of panduratin A was 1 g/ml. These results indicate
that panduratin A has stronger antistaphylococcal activity
against MSSA isolates than erythromycin, gentamicin, levo-
floxacin, linezolid, or tetracycline.
The MRCNS isolates were also resistant to most of the
antimicrobial agents tested. All MRCNS isolates were inhib-
ited by 2 g/ml of vancomycin and 4 g/ml of linezolid.
The MIC range and MIC90 of panduratin A for MRCNS
isolates was 0.125 to 2 g/ml and 1 g/ml, respectively. These
results indicate that antistaphylococcal activity of panduratin A
against MRCNS is equal to that of vancomycin and stronger
than that of linezolid.
Finally, the MIC range of panduratin A against MSCNS
isolates (0.063 to 2 g/ml) was narrower than those of eryth-
romycin, gentamicin, levofloxacin, linezolid, oxacillin, and tet-
racycline. Vancomycin had the narrowest range of MIC (0.063
to 1 g/ml) against MSCNS isolates. Interestingly, the MIC90
of vancomycin against MSCNS isolates was the same as the
MIC90 of panduratin A against MSCNS isolates.
The range of MICs of panduratin A for MRSA and MSSA
were very narrow at 0.5 to 1 g/ml and 0.5 to 2 g/ml, respec-
tively. In contrast, the ranges of panduratin A MICs for
MRCNS and MSCNS were large at 0.125 to 2 g/ml and 0.063
to 2 g/ml. These results could be interpreted to mean that
MRSA and MSSA are composed of only one species of Staph-
ylococcus, S. aureus, whereas MRCNS and MSCNS are com-
posed of different species of Staphylococcus: S. hominis, S.
epidermidis, S. haemolyticus, S. simulans, and S. sciuri. Yong et
al. (17) reported that the ranges of MICs for DA-7867, a novel
oxazolidinone, for MRSA and MSSA were broader than those
for MRCNS and MSCNS. Moreover, the ranges of MICs for
CG400549, a novel FaI inhibitor, for MRSA and MSSA were
very narrow at 0.12 to 0.5 g/ml and 0.12 to 1 g/ml, respec-
tively. In contrast, the ranges of CG400549 MICs for MRCNS
and MSCNS were broad at 0.12 to 16 g/ml and 0.5 to 8 g/ml
(18). Thus, the MICs of panduratin A for MRSA, MSSA,
MRCNS, and MSCNS were in agreement with other reports.
In addition, the MIC of panduratin A against P. intermedia was
2 g/ml, whereas that against P. loescheii was 4 g/ml. They
belong to the same genus, Prevotella, but are different species
(13). Thus, coagulase-negative staphylococci (MRCNS and
MSCNS) have a wider MIC dispersion with panduratin A than
that of coagulase-positive staphylococci (MRSA and MSSA).
The in vitro MBCs of panduratin A with an endpoint after
24 h demonstrated that panduratin A was able to kill staphy-
lococcus strains with MBCs of 8 g/ml for MRSA, MSSA,
and MRCNS. On the other hand, panduratin A can kill
MSCNS with MBCs of4 g/ml. These results were similar to
the MBCs of vancomycin against the clinical staphylococcal
strains (Table 1). These panduratin A MBC results suggest
that panduratin A may be as bactericidal as vancomycin. In
addition, the MBC of panduratin A against a P. gingivalis, P.
FIG. 1. Structure of panduratin A.
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loescheii, and S. mutans was 8 g/ml, and the MBC of pandu-
ratin A against P. intermedia and P. acnes was 4 g/ml (6, 13,
15). Panduratin A has been reported to have the ability to
reduce the biofilm of multispecies oral bacteria in vitro (16). It
would be interesting to evaluate the antibiofilm activity of
panduratin A in reducing staphylococcal biofilms. Further
work toward these objectives may resolve these issues.
In conclusion, panduratin A is an antimicrobial agent with
high in vitro activities against clinical MRSA, MSSA, MRCNS,
and MSCNS, including organisms resistant to other antimicro-
bials. These results suggest that panduratin A should undergo
further testing to assess its potential for the treatment of dis-
eases caused by staphylococci. Obviously, toxicity studies, an-
imal model studies, and human clinical trials will determine
whether in vitro microbiological results translate into a useful
drug for treating human infections.
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